The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 1, 1997, Pages 21-28

  Sarich, Troy ^b   Kalhorn, Thomas ^b   Magee, Sara ^b   Al Sayegh, Faisal ^b   Adams, Stephen ^b   Slattery, John ^b   Goldstein, Joyce ^b   Nelson, Sidney ^b   Wright, James ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; CAFFEINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; MEPHENYTOIN; OMEPRAZOLE; PARACETAMOL; PROTON PUMP INHIBITOR;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANTI-ULCER AGENTS; ANTICONVULSANTS; FEMALE; HUMANS; MALE; MEPHENYTOIN; MIDDLE AGED; OMEPRAZOLE; PHENOTYPE; REFERENCE VALUES;

EID: 0030748504     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90148-X     Document Type: Article

References (38)

1. Hinson JA. Biochemical toxicology of acetaminophen. Rev Biochem Toxicol 1980;2:103-29.
2. Black M. Acetaminophen hepatotoxicity. Annu Rev Med 1984;35:577-93.
3. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990; 10:267-78.
4. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis; I: role of Drug Metabolism. J Pharmacol Exp Ther 1973;187:185-94.
5. Blair IA, Boobis AR, Davies DJ, Cresp TM. Paracetamol oxidation: synthesis and reactivity of N-acetyl-p-benzoquinone imine. Tetrahedron Lett 1980;21:4947-50.
6. Corcoran GB, Mitchell JR, Yaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinone imine. Mol Pharmacol 1980;18:536-42.
7. Dahlin DC, Nelson SD. Synthesis, decomposition kinetics and preliminary toxicological studies on pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen. J Med Chem 1982;25:885-6.
8. Dahlin DC, Miwa GT, Lu AYH, Nelson SD. N-Acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 1984;81:1327-31.
9. Holme JA, Dahlin DC, Nelson SD, Dybing E. Cytotoxic effects of N-acetyl-p-benzoquinone imine, a common arylating intermediate of paracetamol and N-hydroxyparacetamol. Biochem Pharmacol 1984;33: 401-6.
10. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 1989; 271:270-83.
11. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 1993;6:511-8.
12. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993;45:1563-9.
13. +)ATPase. Nature 1981;290:159-61.
14. Lind T, Cederberg C, Ekenved G, Hagland U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated gastric secretion in man. Gut 1983;24:270-6.
15. Diaz D, Fabre I, Daujat M, Aubert BS, Bories P, Michel H, et al. Omeprazole is an aryl hydrocarbonlike inducer of human hepatic cytochrome P-450. Gastroenterology 1990;99:737-47.
16. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992;52:170-80.
17. Quattrochi LC, Tukey RH. Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: transcriptional activation of the human CYP1A1 gene. Mol Pharmacol 1993;43:504-8.
18. Nousbaum JB, Berthou F, Carlhant D, Riche C, Robaszkiewicz M, Gouerou H. Four-week treatment with omeprazole increases that metabolism of caffeine. Am J Gastroenterol 1994;89:371-5.
19. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994;55:402-11.
20. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:773-80.
21. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12:415-6.
22. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl-Puustinen ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
23. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer U, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
24. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer U, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
25. Balian JD, Sukhova N, Harris JW, Pickel L, Goldstein JA, Woosley RL, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
26. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-7.
27. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11.
28. Goldstein JA, Blaisdell J. Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In: Johnson EF, Waterman MR, editors. Methods in enzymology; vol 272, cytochrome P450, part B. San Diego: Academic Press, 1996:210-7.
29. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
30. Sanz EJ, Villén T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989;45:495-9.
31. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, et al. Metoprolol and mephenytoin oxidation polymorphisms in far eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
32. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994;47:1767-76.
33. Xiaodong S, Gatti G, Bartoli A, Cipolla G, Crema F, Perucca E. Omeprazole does not enhance the metabolism of phenacetin, a marker of CYPIA2 activity, in healthy volunteers. Ther Drug Monit 1994;16:248-50.
34. Blanchard J, Sawers SJA. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm 1983;11:109-26.
35. Epstein MM, Nelson SD, Slattery JT, Kalhorn TF, Wall RA, Wright JM. Inhibition of the metabolism of paracetamol by isoniazid. Br J Clin Pharmacol 1991; 31:139-42.
36. Rost KL, Brösicke BH, Heinemeyer G, Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994;20:1204-12.
37. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993;54:142-9.
38. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993;45:1563-9.